(HealthDay News) — Angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) use is not associated with COVID-19 test positivity, according to a study published online in JAMA Cardiology.

Neil Mehta, MBBS, from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and colleagues examined the association between use of ACEIs/ARBs and the likelihood of testing positive for COVID-19 in a retrospective cohort study with overlap propensity score weighting. Data were included for 18,472 patients tested for COVID-19, of whom 12.4% were taking either ACEIs or ARBs.

The researchers observed a positive COVID-19 test result in 9.4% of the patients. Of those who tested positive, 24.3, 9.3, and 6.4% were admitted to the hospital, admitted to an intensive care unit, and required mechanical ventilation, respectively. There was no significant association for ACEI and/or ARB use with COVID-19 test positivity in overlap propensity score weighting (odds ratio, 0.97; 95 percent confidence interval, 0.81 to 1.15).

Continue Reading

“As there may be a risk to withdrawing these agents, our study, showing no significant greater susceptibility with regard to test positivity, supports the recommendations of several professional societies that have recommended continuation of these medications,” the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Mehta N, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. doi: 10.1001/jamacardio.2020.1855

Thomas LE, Bonow RO, Pencina MJ, et al. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. doi: 10.1001/jamacardio.2020.1874

Related Articles